Kevzara (sarilumab subcutaneous injection – Regeneron/SanofiAventis) — Cigna

Initial criteria

• Patient age > 18 years
• Patient has tried ONE conventional synthetic DMARD for at least 3 months
• Medication is prescribed by or in consultation with a rheumatologist

Reauthorization criteria

• Patient has been established on therapy for at least 6 months
• Patient experienced a beneficial clinical response when assessed by at least one objective measure OR improvement in at least one symptom

Approval duration

initial 6 months; reauth 1 year